Corbus Pharmaceuticals Holdings, Inc. (CRBP), a U.S.-based pharmaceutical company, reported a wider loss in the second quarter.
The company reported a net loss of $17.7 million or $1.44 per share in the second quarter of 2025, compared to a net loss of $10 million or $0.90 per share.
The rise in losses during this quarter was caused by increased operating expenses, particularly driven by higher clinical development expenses.
Tuesday, CRBP closed at $8.90, down 4.71%, and is trading flat after hours on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.